Drug intelligence / Profile preview

HPvax

Development stage: Unknown
Lead developer: Popular Pharmaceuticals
Modality: Vaccines & Immunotherapeutics
Administration: Intramuscular

Overview

HPvax is a non-infectious, recombinant protein-based vaccine designed to provide acquired immunity against Human Papillomavirus (HPV) types 16 and 18. It is manufactured by Popular Pharmaceuticals Ltd. and is indicated for the prevention of HPV infection, premalignant cervical lesions, cervical cancer, adenocarcinoma in situ, and cervical intraepithelial neoplasia caused by these specific oncogenic HPV types. The vaccine works by introducing virus-like particles (VLPs) composed of the major capsid L1 protein of HPV types 16 and 18, which stimulate the immune system to produce neutralizing antibodies.

Brand names: HPvax
Other names: Human Papilloma virus Bivalent (Types 16 and 18) Vaccine, Recombinant

Targets

HPV L1 (Human papillomavirus L1 capsid protein)

Beyond the preview

Go deeper on HPvax.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on HPvax.

Explore the full profile